Effects of hepatocyte growth factor on the expression of matrix metalloproteinases and their tissue inhibitors during the endometrial cancer invasion in a three-dimensional coculture

International Journal of Gynecological Cancer

Volumn 13, Issue 1, 2003, Pages 53-60

  Park, Y H ^a   Ryu, Hee Sug ^a   Choi, D S ^a   Chang, K H ^a   Park, D W ^a,b   Min, C K ^a  

^a Ajou University School of Medicine   (South Korea)

^b Ajou University   (South Korea)

Author keywords

3D coculture; Endometrial cancer; Hepatocyte growth factor; Matrix metalloproteinases

Indexed keywords

GELATINASE A; GELATINASE B; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; ENZYME INDUCTION; HUMAN; HUMAN CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; ZYMOGRAPHY;

ADENOCARCINOMA; COCULTURE TECHNIQUES; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TISSUE INHIBITOR OF METALLOPROTEINASES; TUMOR CELLS, CULTURED;

EID: 0037222089     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13033.x     Document Type: Article

References (51)

1. Park DW, Ryu HS, Choi DS, Park YH, Chang KH, Min CK. Localization of matrix metalloproteinases on endometrial cancer cell invasion in vitro. Gynecol Oncol 2001;82:442-9.
2. Ponzetto C, Bardelli A, Zhen Z et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
3. Nakamura T, Nawa K, Ichihara A, Kaise N, Nishino T. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett 1987;224:311-8.
4. Nakamura T, Nishizawa T, Hagiya M et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
5. Park M, Dean M, Kaul K et al. Sequence of Met protooncogene cDNA has features characteristic of the tyrosine kinase family of growth factor receptors. Proc Natl Acad Sci USA 1987;84:6379-83.
6. Zhu H, Naujoskas MA, Fixman ED, Torrosian K, Park M. Tyrosine 1356 in the carboxyl-terminal tail of the HGF/SF receptor is essential for the transduction of signals for cell motility and morphogenesis. J Biol Chem 1994;269:29943-8.
7. Beviglia L, Kramer RH. HGF induces FAK activation and integrin mediated adhesion in MTLn3 breast carcinoma cells. Int J Cancer 1999;26:640-9.
8. Matsumoto K, Matsumoto K, Nakamura T, Kramer RH. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J Biol Chem 1994;269:31807-13.
9. Victoria BJ, Eileen MS, David V, Scott K. Hepatocyte growth factor (HGF) induces invasion of endometrial cancer cell lines in vitro. Gynecol Oncol 1999;73:265-72.
10. Wang H, Joan AK. Hepatocyte growth factor enhances MMP activity in human endothelial cells. Biochem Biophys Res Commun 2000;272:900-5.
11. Liotta LA, Abe S, Robey PG, Martin GR. Preferential digestion of basement membrane collagen by an enzyme derived from a metastatic murine tumor. Proc Natl Acad Sci USA 1979;75:2268-72.
12. Yurchenco PD, Schittney JC. Molecular architecture of basement membranes. FASEB J 1990;4:1577-90.
13. Barsky SH, Siegal GP, Jarnotta F, Liotta LA. Loss of basement membrane components by invasive tumors but not by their benign counterparts. Lab Invest 1983;49:140-7.
14. Woessner JF Jr. The matrix metalloproteinase family. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego: Academic Press, 1998; 1-14.
15. Sato H, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in tumor metastasis. J Biochem 1996;119:209-15.
16. Kinoh H, Sato H, Tsunezuka Y, Takino T, Kawashima A, Okada Y. MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis. J Cell Sci 1996;109:953-9.
17. Strongin AY, Collier IE, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type collagenase: isolation of the activated form of the membrane metalloproteinase. J Biol Chem 1995; 270:5331-8.
18. Knäuper V, Will H, Lopez-Otin C et al. Cellular mechanisms for human procollagenase-13 (MMP-13) activation. evidence that MT1-MMP (MMP-14) and gelatinase A (MMP-2) are able to generate active enzyme. J Biol Chem 1996;271:17124-31.
19. Fini ME, Cook JR, Mohan R. Regulation of MMP gene expression. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego: Academic Press, 1998: 299-356.
20. Knäuper V, Murphy G. Membrane-type matrix metalloproteinases and cell-surface associated activation cascades for matrix metalloproteinases. In: Parks WC, Mecham RP, eds. Matrix Metalloproteinases. San Diego: Academic Press, 1998: 199-218.
21. Brooks PC, Strömbald S, Sanders LC et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;85:683-93.
22. Docherty AJ, Lyons A, Smith BJ, Wright EM, Stephens PE, Harris TJ. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985;318:66-9.
23. Murphy G, Crabbe T. Gelatinases A and B. Meth Enzymol 1995;248:470-84.
24. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8.
25. Collier IE, Wilhelm SM, Eisen AZ et al. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem 1988;263:6579-87.
26. Pyke C, Ralfkiaer E, Huhtala P, Hurskainen T, Dano K, Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res 1992;52:1336-41.
27. Zucker S, Drews M, Conner C et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 1998;273:1216-22.
28. Nagase H, Ogata Y, Suzuki K, Enghild JJ, Salvesen G. Substrate specificities and activation mechanisms of matrix metalloproteinases. Biochem Soc Trans 1991;19:715-8.
29. Okada Y, Tsuboi S, Tsuda Y, Nagamatsu Y, Yamamoto J. Synthesis of a trihexacontapeptide corresponding to the sequence 8-70 of eglin c and studies on the relationship between the structure and the inhibitory activity against human leukocyte elastase, cathepsin G and alpha-chymotrypsin. FEBS Lett 1990;272:113-6.
30. Friedman R, Fuerst TR, Bird RE et al. Domain structure of human 72-kDa gelatinase/type IV collagenase: characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem 1992; 267:15398-405.
31. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 1998;273:16098-103.
32. Davies B, Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993;67:1126-31.
33. Zeng ZS, Guillem JG. Co-localisation of matrix metalloproteinase-9 mRNA and protein in human colorectal cancer stromal cells. Br J Cancer 1996;74:1161-7.
34. Nakagawa H, Yagihashi S. Expression of type IV collagen and its degrading enzymes in squamous cell carcinoma of lung. Jap J Cancer Res 1994;85:934-8.
35. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M. In situ hybridization studies of metalloproteinase 2 and 9 and timp-1 and timp-2 expression in human prostate cancer. Clin Exp Metastasis 1997;15:246-58.
36. Gress TM, Mueller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in situ localization of genes coding for extracellular matrix proteins degrading proteases in pancreatic cancer. Int J Cancer 1995; 62:407-13.
37. Young TN, Rodriguez GC, Rinehart AR, Bast RC Jr, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol 1996;62:89-99.
38. Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 1972;15:1012-9.
39. McCawley LJ, O'Brien P, Hudson LG. Epidermal growth factor (EGF) - and scatter factor/hepatocyte growth factor (SF/HGF) -mediated keratinocyte migration is coincident with induction of matrix metalloproteinase (MMP) -9. J Cell Physiol 1998;176:255-65.
40. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
41. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135-49.
42. Fiedler IJ. Molecular biology of cancer: Invasion and metastasis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th edn. Philadelphia: Lippincott-Raven, 1997:135-52.
43. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001;294:1708-12.
44. Hofmann A, Laue S, Rost AK, Scherbaum WA, Aust G. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Thyroid 1998;8:203-14.
45. Liu Y, Rajur K, Tolbert E, Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 2000;58:2028-43.
46. Hanzawa M, Shindoh M, Higashino F et al. Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. Carcinogenesis 2000;21:1079-85.
47. Haruyama T, Ajioka I, Akaike T, Watanabe Y. Regulation and significance of hepatocyte-derived matrix metalloproteinases in liver remodeling. Biochem Biophys Res Commun 2000;272:681-6.
48. Zambonin G, Camerino C, Greco G, Patella V, Moretti B, Grano M. Hydroxyapatite coated with hepatocyte growth factor (HGF) stimulates human osteoblasts in vitro. J Bone Joint Surg Br 2000;82:457-60.
49. Tamakoshi K, Kikkawa F, Nawa A et al. Different pattern of zymography between human gynecologic normal and malignant tissues. Am J Obstet Gynecol 1994;171:478-84.
50. Bae-Jump V, Segreti EM, Vandermolen D, Kauma S. Hepatocyte growth factor induces invasion of endometrial carcinoma cell lines in vitro. Gynecol Oncol 1999;73:265-72.
51. Yoshida S, Harada T, Iwabe T et al. Induction of hepatocyte growth factor in stromal cells by tumor-derived basic fibroblast growth factor enhances tumor growth and invasion of endometrial cancer. J Clin Endocrinol Metab 2002;87:2376-83.